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To the Editor,
In their recent article, Stopeck et al. [1] concluded that
denosumab confirms its known safety profile even after long-
term exposure, or after switching to it from zoledronic acid, and
that osteonecrosis of jaws (ONJ) rates increased with increasing
exposure to antiresorptives, consistent with previous reports.
This is based on the open label extension phase of two phase
3 studies in patients with breast and prostate cancer with bone
metastases who were randomized to receive denosumab or zo-
ledronic acid (ZA) [2, 3]. The patients were offered open-label
denosumab for up to an additional 2 years after the results of the
primary analysis, favorable for denosumab on several aspects.
Patients initially randomized to denosumab (denosumab/
denosumab group) continued to receive denosumab at
120 mg Q4W whereas patients on ZA were switched to
denosumab in the open-label phase (ZA/denosumab group) at
120 mg Q4W starting 4 weeks from their last ZA dose. Patients
who declined further therapy in the open-label extension phase,
or who did not complete the blinded treatment phase, continued
follow-up for survival every 12weeks (Q12W) for up to 2 years
after their last dose.
We collected data from the text and the tables of the paper
published by Stopeck et al. [1] and summarized them in a new
table (Table 1).
Although authors’ conclusions are quite reassuring both in
terms of denosumab safety and efficacy, it is noteworthy that
the median exposure of patients to denosumab in the extension
phase study is lower than expected, even in the presence of a
longer range. The final median exposure of the 318
denosumab/denosumab breast cancer patients is 19.1 months
(range 0.1–59.8), not much longer than that registered for the
whole cohort of the 1019 breast cancer patient population en-
rolled in the blinded phase, that was 17.6 months (range 0–
23.7). As far as prostate cancer patients are concerned, the
median denosumab exposure was 12.0 months (range 0.1–
67.2) for the 147 denosumab/denosumab patients from the
extension study versus 12.0 months (range 0.1–23.3) for the
942 patients enrolled in the original randomized trial. We could
not work out from the paper the median denosumab exposure
for 318 breast and 147 prostate cancer patients of the extension
study denosumab/denosumab population in the previous
blinded phase. This appears to us a weakness of the article.
Interestingly, the frequency of ONJ cases in the open label
extension study appears substantially higher than what is
found in the initial blinded phase (ONJ frequency ranging
from 1 to 2 %) [2, 3] despite median denosumab exposure
was not significantly longer in the former. The crude ONJ
figures increased both in denosumab/denosumab groups and
in ZA/denosumab populations: ONJ cases were respectively
20/318 (6.3 %) in breast patients and 12/147 (8.2 %) in pros-
tate patients in the denosumab/denosumab group, whereas
they were 18/334 (5.4 %) breast patients and 7/118 (5.9 %)
prostate patients in the ZA/denosumab group.
Such an increase in ONJ frequency highlights the need for
longer patients’monitoring and the adoption of nonparametric
actuarial estimation (Kaplan-Meier), as done in other studies
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[4–9], to obtain the projected individual ONJ risk at 2, 3, and
4 years of treatment. Separate analysis should be performed
by Stopeck et al. [1] for breast and prostate cancer patients,
showing these latter ones a similar ONJ rate increase even
after shorter median drug exposure.
Saad et al. published in 2012 [10] the integrated analysis of
the results of three pivotal trials of blinded comparison be-
tween denosumab and zoledronic acid: they also reported
the number of Bpotential ONJ^ cases that were initially regis-
tered as spontaneously reported by investigators or on the base
of 36 MedDRA (Medical Dictionary for Regulatory
Activities) adverse oral event terms. BPotential ONJ^ cases,
defined by the presence of clinical sign and symptoms sug-
gestive of ONJ, were three times higher than the finally
Badjudicated ONJ^ cases: 276/5723 (4.8 %) versus 89/5723
(1.5 %). Of importance, such data were recorded after a rela-
tively short observation time, being the median (Q1, Q3) time
on study 12.1 (5.4, 19.4) months for patients in the ZA group
and 12.6 (5.6, 19.4) months for patients in the denosumab
group [10]. We believe that it would be of great value if the
authors of the extension study [1] could report the number of
Bpotential ONJ^ cases (defined as above) observed in the
breast and prostate cancer population of the extension study,
and compare them with those of the blinded study, and those
among patients who declined shift to denosumab, if available.
There are two burning aspects that we would like to ad-
dress: the definition of ONJ and the optimal duration of
antiresorptive (bisphosphonates or denosumab) treatment.
The definition of ONJ is highly debated and controversial,
with evident consequences on clinical practice, trials, and epi-
demiological studies. The initial definition of ONJ as proposed
and published in 2007 by a Task Force of the American
Association of Oral Maxillofacial Surgeons (AAOMS) [11]
was based on the presence of exposed bone in the oral cavity
lasting at least 8 weeks in patients treated with bisphosphonates
who did not receive radiation therapy of the head and neck
region. This case definition was adopted to adjudicate ONJ
patients in clinical trials on bisphosphonates and denosumab.
In recent years, increasing evidence of symptomatic cases
of medication-related jawbone alterations without frank bone
exposure has raised skepticism among clinicians who
questioned the original BRONJ (Bisphosphonate-Related
ONJ) case definition, assuming that it could have contributed
to epidemiological estimates being inconsistent because it ex-
cluded cases with no obviously exposed bone [12]. In 2009,
the AAOMS Task Force updated its recommendations on
BRONJ [13] by adding the Bstage 0^ to classify patients pre-
senting with a number of oral signs and symptoms other than
bone exposure but, unfortunately, they did not modify the
2007 definition. The contradictory nature of the position paper
was then underlined by several authors and researchers,
claiming for a broader definition to include the Bnon-exposed^
ONJ variant [14, 15].
Hence, the AAOMS Task Force released in 2014 a third
position paper [16] that partially expanded the definition of
disease to include cases with Bbone that can be probed through
an intraoral or extraoral fistula in the maxillofacial region that
has persisted for longer than 8 weeks^ and confirmed the ex-
istence of a Bstage 0 category^ for patients with signs and
symptoms other than bone exposure and soft-tissue fistulas
(Bnonspecific symptoms or clinical and radiographic abnor-
malities that might be due to exposure to an antiresorptive
agent^) [16]. The original acronym BRONJ (bisphosphonate-
related ONJ) was also implemented to include cases of ONJ
that were reported after treatment with antiangiogenic agents
and denosumab, so that the terms ONJ and MRONJ
(medication-related ONJ) are now more correctly used [16].
The AAOMS experts admitted the risk of underestimation of
such a definition based only on two clinical signs (bone expo-
sure and fistula), choosing that risk versus the opposite risk of
an eventual overestimation (inducible, according to them, by
Bcases with radiographic signs alone^) [16]. Overall, these
long-lasting controversies on definition are still likely to cause
incorrect estimation of ONJ incidence in clinical studies, as well
as patient selection and a too-short follow-up duration [17]. On
the other hand, an overly restricted ONJ definition might result
in late diagnosis of ONJ in clinical practice, exposing patients to
rare but life-threatening complications [18, 19].
The optimal duration of bone metastatic treatment with
antiresorptive drugs (i.e., bisphosphonates and denosumab)
is yet to be defined.
Most guidelines recommended the long-lasting administra-
tion of antiresorptives (that is, till to deterioration of patient
general conditions) based on the substantial lack of demon-
strated serious side effects in published trials [20, 21]. After
reporting several cases of renal toxicity and ONJ, especially in
patients exposed for longer time, since years 2006–2007 some
guidelines indicated treatment with bisphosphonates for 1 or
2 years, and then Btailoring^ the therapy, for both myeloma
patients [22–24] and bone metastases of solid tumors [25].
Despite this, the ASCO did not change recommendations for
bone metastatic breast cancers till 2011, after approval of
denosumab [26]: it was underlined that BThere are no pro-
spective clinical RCT data to support the continuation of
bone-modifying agent therapy beyond 1 year^ whereas in
the summary table, at the voice BOptimal duration^ it was
reported BUnchanged in substance from 2003^ (that is
Bcontinued until evidence of substantial decline in a patient’s
general performance status.^) [26].
In conclusion, more data on oral discomfort and more
follow-up data from the extension study by Stopeck et al. [1]
could be of great value to help patients and prescribers of
antiresorptive drugs to share a tailored treatment with the most
favorable cost-effectiveness, based on sound evaluation of in-
dividual risk factors for safety, together with undeniably favor-
able effects on skeletal-related effects (SRE) and quality of life.
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